OQROGet OQRO Pro
Insider trade

Acumen Pharmaceuticals (ABOS)CEO sold ~$17K

Daniel Joseph Oconnell, CEO at Acumen Pharmaceuticals, sold ~$17K of Acumen Pharmaceuticals shares.

~$17K
Approx. value · 9,346 sh @ $1.81
884K
Holds after · shares reported
Traded
Jan 21, 2026
Filed
Jan 23, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 5, 2026Insider · 5 peopleInsiders: 5 sales (~$41K)
  2. Jan 6, 2026Insider · 5 peopleInsiders: 6 sales (~$62K)
  3. Jan 7, 2026Insider · 6 peopleInsiders: 8 sales (~$119K)
  4. Jan 8, 2026Insider · 5 peopleInsiders: 6 sales (~$113K)
  5. Jan 9, 2026Insider · 2 peopleInsiders: 2 sales (~$32K)
  6. Jan 12, 2026Insider · 2 peopleInsiders: 2 sales (~$24K)
  7. Jan 21, 2026 · this disclosureInsiderCEO sold ~$17K of ABOS shares in the open market

What came next

  1. Jan 21, 2026Insider · 4 peopleInsiders: 4 sales (~$17K)
  2. Jan 22, 2026Insider · 5 peopleInsiders: 5 sales (~$13K)
  3. Jan 23, 2026InsiderOfficer sold ~$11K of ABOS shares in the open market
  4. Jan 26, 2026InsiderOfficer sold ~$45K of ABOS shares in the open market
  5. Jan 28, 2026InsiderOfficer sold ~$8K of ABOS shares in the open market
  6. Feb 27, 2026InsiderOfficer sold ~$28K of ABOS shares in the open market
  7. Mar 6, 2026InsiderOfficer sold ~$6.8K of ABOS shares in the open market
  8. Mar 13, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
  9. Mar 26, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
  10. May 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Acumen Pharmaceuticals

OQRO holds no insider, Congress, fund or contract record for Acumen Pharmaceuticals dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABOS page.

Other recent filings by Daniel Joseph Oconnell, Chief Executive Officer

The full history of Daniel Joseph Oconnell, Chief Executive Officer is on the profile page.

How this filing works

Other disclosures at Acumen Pharmaceuticals

Everything OQRO holds on this company is on its ABOS page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data